Skip to main content
Caplight Logo









Kanjin Therapeutics

Kanjin Therapeutics

Private
DelawareHealthcare & Life Scienceshttps://kanjin-tx.com

Last Round

Seed

Apr 27, 2026

Total Funding Raised

$330,000

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Kanjin Therapeutics is a biotechnology company developing advanced therapeutics to halt and potentially restore kidney function, with the goal of eliminating the need for dialysis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

chronic kidney diseaseCKDpre-clinical biotechdrug discoverydrug developmentnephrologybiotechnologynovel drug targetbiopharmapharmaceutical licensingrenal dysfunctionuniversity spinouttranslational science

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kanjin Therapeutics Comparables

Compare Kanjin Therapeutics with similar companies based on industry and business-model similarity.

Kanjin Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
R1 Therapeutics
81%
Walden Biosciences
81%
Rege Nephro Co., Ltd.
78%

Kanjin Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedApr 27, 2026

Key People

Founding team and executive leadership

Caleb Bell

Co-Founder and CEO

Founding Team

Kanjin Therapeutics Investors

Notable investors and investment history

Kanjin Therapeutics investors
InvestorRounds
Kyoto University Innovation CapitalSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 27, 2026

    $330K round led by Kyoto University Innovation Capital

Kanjin Therapeutics Filings

Explore SEC and related filing metadata, where available.

Kanjin Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Kanjin Therapeutics's valuation, stock price, and market status.

Is Kanjin Therapeutics a public or private company?

Kanjin Therapeutics is a private company.

What is the current stock price of Kanjin Therapeutics?

Kanjin Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Kanjin Therapeutics worth (valuation)?

Valuation information for Kanjin Therapeutics is not publicly available.

Can I buy Kanjin Therapeutics stock?

Kanjin Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Kanjin Therapeutics's last funding round?

Funding round information for Kanjin Therapeutics is not publicly available.

Who are the main investors in Kanjin Therapeutics?

Investor information for Kanjin Therapeutics is not publicly disclosed.

Will Kanjin Therapeutics IPO soon?

No public IPO plans have been announced for Kanjin Therapeutics.

How can I track Kanjin Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Kanjin Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersDelaware
Employee Range3
Year Founded2025
Last FundingApr 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?